<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223337</url>
  </required_header>
  <id_info>
    <org_study_id>200231</org_study_id>
    <nct_id>NCT03223337</nct_id>
  </id_info>
  <brief_title>Daprodustat Hepatic Impairment Study</brief_title>
  <official_title>A Phase 1, Open-label, Non-randomized, Parallel Group, Single-dose Adaptive Study in Adults With Hepatic Impairment and Matched, Healthy Control Participants With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Daprodustat (GSK1278863), is a small molecule currently in development for the treatment of
      anemia of chronic kidney disease (CKD). Results of the earlier studies shows that liver is
      involved in the clearance of Daprodustat and hence, hepatic impairment can affect Daprodustat
      levels in the body. This single dose study will assess the effect of liver impairment on the
      pharmacokinetics (PK) and pharmacodynamics (PD) of daprodustat. The study will be conducted
      in two parts, Part 1 will include subjects with moderate hepatic impairment and matched
      healthy control subjects whereas Part 2 will include subjects will either mild or severe
      hepatic impairment and matched healthy control subjects. Approximately 8 subjects will be
      included in each of the group and all subjects will receive 6 milligram (mg) of daprodustat
      as a single oral dose in the fasted state. Total duration of participation in the study for a
      subject will be up to 7 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Actual">August 20, 2018</completion_date>
  <primary_completion_date type="Actual">August 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will receive 6 mg of daprodustat as a single oral dose in parallel way throughout the study period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study and no blinding will be performed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2) , GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percentage AUCex of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC (0-t) of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax of GSK1278863 and Its Metabolites.</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: T1/2 of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tmax of GSK1278863 and Its Metabolites</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites</measure>
    <time_frame>3 hours, 12 hours and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites</measure>
    <time_frame>3 hours, 12 hours and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites</measure>
    <time_frame>3 hours, 12 hours and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818, GSK2506102, GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites</measure>
    <time_frame>3 hours, 12 hours and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites (GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13)). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
    <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points. Pharmacodynamic Population comprised of all participants in the Safety Population who had at least one pharmacodynamic assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax, EPO Following Administration of GSK1278863</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
    <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
    <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Tmax, EPO Following Administration of GSK1278863</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
    <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
    <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC (0-t, EPO) Following Administration of GSK1278863</measure>
    <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
    <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. Safety Population comprised of all participants who received at least one dose of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With AEs and SAEs</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline</measure>
    <time_frame>Baseline (Screening) and up to Day 16</time_frame>
    <description>Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter (g/L) for hemoglobin, &lt;3 or &gt;20 x10^9 cells per liter (cells/L) for leukocytes, &lt;0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 x10^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given [e.g.], High to High), or whose value became within range, were recorded in &quot;To within Range or No Change&quot; category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline</measure>
    <time_frame>Baseline (Screening) and up to Day 16</time_frame>
    <description>Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, &lt;3 or &gt;20 x10^9 cells/L for leukocytes, &lt;0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 x10^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in &quot;To within Range or No Change&quot; category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</measure>
    <time_frame>Baseline (Screening) and up to Day 16</time_frame>
    <description>Blood samples were collected for analysis of following parameters. PCI ranges were &lt;30g/L (albumin), &lt;2 or &gt;2.75 millimoles/L(mmol/L) (calcium), &lt;3 or &gt;9mmol/L(glucose), &gt;=2 times Upper limit of Normal(ULN) units/L(U/L) (alanine aminotransferase [ALT]), &gt;=2 times ULN U/L (alkaline phosphatase), &gt;=2 times ULN U/L(aspartate aminotransferase [AST]), &gt;=1.5 times ULN micromoles/L (µmol/L)(bilirubin), &lt;3 or &gt;5.5mmol/L(potassium), and &lt;130 or &gt;150mmol/L(sodium). Participants were counted in worst case category that their value changes to (low,within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</measure>
    <time_frame>Baseline (Screening) and up to Day 16</time_frame>
    <description>Blood samples were collected for analysis of following parameters. PCI ranges were &lt;30g/L (albumin), &lt;2 or &gt;2.75 mmol/L (calcium), &lt;3 or &gt;9mmol/L (glucose), &gt;=2 times ULN U/L (ALT), &gt;=2 times ULN U/L (alkaline phosphatase), &gt;=2 times ULN U/L (AST), &gt;=1.5 times ULN µmol/L (bilirubin), &lt;3 or &gt;5.5 mmol/L (potassium), and &lt;130 or &gt;150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Abnormal Urinalysis Findings</measure>
    <time_frame>Up to Day 16</time_frame>
    <description>Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants With Abnormal Urinalysis Findings</measure>
    <time_frame>Up to Day 16</time_frame>
    <description>Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>Subjects with moderate hepatic impairment: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Healthy controls: Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with either mild or severe hepatic impairment: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched healthy controls: Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daprodustat (GSK1278863)</intervention_name>
    <description>Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.</description>
    <arm_group_label>Matched Healthy controls: Part 1</arm_group_label>
    <arm_group_label>Matched healthy controls: Part 2</arm_group_label>
    <arm_group_label>Subjects with either mild or severe hepatic impairment: Part 2</arm_group_label>
    <arm_group_label>Subjects with moderate hepatic impairment: Part 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For all subjects:

          -  Subject must be at least 18 years of age inclusive, at the time of signing the
             informed consent.

          -  Hemoglobin values at screening &lt;=16.0 gram per deciliter (g/dL) for males and &lt;=14.0
             g/dL for females.

          -  Body weight &gt;=45 kilograms (kg) and body mass index (BMI) within the range 18-40 kg
             per meter square (kg/m^2) (inclusive).

          -  Male or female subjects will be included. A female subject is eligible to participate
             if she is not breastfeeding, and at least one of the following applies: Not pregnant
             as confirmed by two pregnancy tests; Not a woman of childbearing potential (WOCBP);
             For WOCBP that are currently utilizing a highly-effective contraceptive method prior
             to enrolment, agrees to follow the contraceptive guidance during the treatment period
             to the follow-up visit.

          -  Capable of giving signed informed consent form.

        Additional inclusion criteria for Hepatically-Impaired subjects:

          -  Subjects in Part 1 with Moderate Hepatic Impairment Only (Cohort 1): Is considered to
             have moderate hepatic impairment (of any etiology) and has been clinically stable for
             at least 1 month prior to screening. To be classified as having moderate hepatic
             impairment, subjects must have a Child-Pugh (Class B) score of 7-9 AND previous
             confirmation of liver cirrhosis by liver biopsy or other medical imaging technique
             (including laparoscopy, computerized tomography (CT) scan, magnetic resonance imaging
             (MRI) or ultrasonography) associated with an unambiguous medical history (such as
             evidence of portal hypertension).

          -  Subjects in Part 2 with Mild OR Severe Hepatic Impairment Only (Cohort 3; if
             conducted): Is considered to have mild or severe hepatic impairment (of any etiology)
             and has been clinically stable for at least 1 month prior to screening. To be
             classified as having mild OR severe hepatic impairment, subjects must have: classified
             as having mild hepatic impairment, subjects must have a Child- Pugh (Class A) score of
             5-6 AND previous confirmation of chronic liver disease by liver biopsy or other
             medical imaging technique (including laparoscopy, CT scan, MRI or ultrasonography)
             associated with an unambiguous medical history (such as evidence of portal
             hypertension); classified as having severe hepatic impairment, subjects must have
             Child- Pugh (Class C) score of 10-13 AND previous confirmation of chronic liver
             disease by liver biopsy or other medical imaging technique (including laparoscopy, CT
             scan, MRI or ultrasonography) associated with an unambiguous medical history (such as
             evidence of portal hypertension).

          -  Supplemental inclusion criteria for ALL hepatically-impaired subjects: Chronic (&gt;6
             months), stable (no acute episodes of illness due to deterioration in hepatic function
             within the previous 1 month prior to screening) hepatic impairment due to any
             etiology. Subjects must also remain stable throughout the Screening period. Assessment
             of the stability of the subjects hepatic function will be determined by the
             investigator.

        Additional inclusion criteria for healthy control subjects:

          -  Healthy control subjects will be matched for age +/-10 years to subjects in the
             respective hepatic impairment cohort but must also be at least 18 years of age
             inclusive, at the time of signing the informed consent.

          -  Healthy as determined by the investigator or medically qualified designee based on a
             medical evaluation including medical history, physical examination, laboratory tests
             and cardiac monitoring.

          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not
             specifically listed in the inclusion or exclusion criteria, outside the reference
             range for the population being studied may be included only if the investigator and/or
             the Medical Monitor agree and document that the finding is unlikely to introduce
             additional risk factors and will not interfere with the study procedures.

          -  Healthy control subjects will be matched for BMI +/-15% to subjects in the respective
             hepatic impairment cohort but must also remain in the range of body weight &gt;=45 kg and
             BMI within the range 18-38 kg/m^2 (inclusive).

        Exclusion Criteria:

        For all subjects:

          -  QT interval corrected for heart rate according to Fridericia's formula (QTcF) &gt;500
             milliseconds (msec).

          -  Recent history of deep vein thrombosis, pulmonary embolism or other thrombosis related
             condition. Any prior medical history in these areas will be reviewed and approved by
             the PI and the sponsor's Medical Monitor on a case by case basis as needed.

          -  Myocardial infarction or acute coronary syndrome, stroke or transient ischemic attack
             within the 12 weeks prior to enrollment.

          -  Subjects with a pre-existing condition (other than liver disease) interfering with
             normal gastrointestinal anatomy or motility that could interfere with the absorption,
             metabolism, and/or excretion of daprodustat.

          -  Subjects that have undergone cholecystectomy within the past 3 months.

          -  Subjects with chronic inflammatory joint disease (example, scleroderma, systemic lupus
             erythematosis, rheumatoid arthritis).

          -  History of malignancy within the prior 2 years or known kidney mass &gt;3 centimeter (cm)
             (end stage renal disease subjects with impairment only) OR currently receiving
             treatment for cancer. ONLY exception is localized squamous cell or basal cell
             carcinoma of the skin definitively treated 12 weeks prior to enrollment.

          -  Class IV heart failure, as defined by the New York Heart Association (NYHA) functional
             classification system.

          -  Current enrolment or past participation (i.e., administration of last dose of
             investigational study treatment) within the last 30 days (or 5 half-lives, whichever
             is longer) before Day 1 in this or any other clinical study involving an
             investigational study treatment or any other type of medical research.

        Exclusion criteria for Hepatically-Impaired subjects:

          -  Present of 8 times Upper limit of normal (ULN) elevations in Aspartate
             aminotransferase (AST), Alanine aminotransferase (ALT), or bilirubin.

          -  Subjects with any other medical condition which, in the judgment of the investigator
             and Medical Monitor, could jeopardize the integrity of the data derived from that
             subject or the safety of the subject.

          -  Subjects with advanced ascites (Grade 3).

          -  Subjects with refractory encephalopathy as judged by the investigator or significant
             Central Nervous System (CNS) disease (example dementia, or seizures) which the
             investigator considers will interfere with the informed consent, conduct, completion,
             or results of this trial or constitutes an unacceptable risk to the subject.

          -  Subjects with functional Transjugular Intrahepatic Portosystemic Shunt (TIPS)
             placement.

          -  Presence of hepatopulmonary or hepatorenal syndrome.

          -  Presence of primarily cholestatic liver diseases.

          -  History of liver transplantation.

          -  Subjects with signs of active infection, including active spontaneous bacterial
             peritonitis.

          -  Subjects with unstable cardiac function or subjects with hypertension whose blood
             pressure is not controlled (based on the investigator's discretion).

          -  Diabetic subjects whose diabetes is not controlled (based on the investigator`s
             discretion).

        Exclusion criteria for healthy control subjects:

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening or Positive Hepatitis C
             antibody test result at screening or within 3 months before the first dose of study
             treatment.

          -  Positive pre-study drug/alcohol screen.

          -  Positive human immunodeficiency virus (HIV) antibody test.

          -  Regular use of known drugs of abuse.

          -  Regular alcohol consumption within 6 months prior to the study defined as an average
             weekly intake of &gt;14 drinks. One drink is equivalent to 12 g of alcohol: 12 ounces
             (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof
             distilled spirits. One unit is equivalent to 8 g of alcohol: a half-pint
             (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of
             spirits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <results_first_submitted>June 24, 2019</results_first_submitted>
  <results_first_submitted_qc>August 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK1278863</keyword>
  <keyword>Daprodustat</keyword>
  <keyword>Healthy control</keyword>
  <keyword>Single dose</keyword>
  <keyword>Hepatic Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03223337/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03223337/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a two part study in adults with moderate (Part 1) and potentially mild (Part 2) hepatic impairment and matched, healthy control participants with normal hepatic function. This study was conducted at two centers in the United States of America (USA).</recruitment_details>
      <pre_assignment_details>All participants received 6 milligrams (mg) of daprodustat (GSK1278863) as a single oral dose in the fasted state. A total number of 16 participants were enrolled in Part 1 and 21 participants were enrolled in Part 2 of the study. In total 37 participants were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Moderate Hepatic Impairment Participants</title>
          <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Healthy Participants</title>
          <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
        </group>
        <group group_id="P3">
          <title>Part 2: Mild Hepatic Impairment Participants</title>
          <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
        </group>
        <group group_id="P4">
          <title>Part 2: Healthy Participants</title>
          <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 (Up to 16 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 (Up to 16 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Moderate Hepatic Impairment Participants</title>
          <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: Healthy Participants</title>
          <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
        </group>
        <group group_id="B3">
          <title>Part 2: Mild Hepatic Impairment Participants</title>
          <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
        </group>
        <group group_id="B4">
          <title>Part 2: Healthy Participants</title>
          <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.5" spread="6.00"/>
                    <measurement group_id="B2" value="57.6" spread="7.15"/>
                    <measurement group_id="B3" value="61.9" spread="7.55"/>
                    <measurement group_id="B4" value="58.7" spread="8.03"/>
                    <measurement group_id="B5" value="59.7" spread="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>BLACK OR AFRICAN AMERICAN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASIAN - EAST ASIAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WHITE - ARABIC/NORTH AFRICAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.2407" spread="111.1"/>
                    <measurement group_id="O2" value="148.3225" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6352" spread="56.9"/>
                    <measurement group_id="O2" value="47.1340" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5557" spread="67.4"/>
                    <measurement group_id="O2" value="28.9896" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8212" spread="43.9"/>
                    <measurement group_id="O2" value="11.2658" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9398" spread="49.2"/>
                    <measurement group_id="O2" value="20.9224" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0606" spread="34.0"/>
                    <measurement group_id="O2" value="39.6044" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric Least Square(LS) Mean</param_type>
            <param_value>1.9973</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1063</ci_lower_limit>
            <ci_upper_limit>3.6057</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.6471</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1267</ci_lower_limit>
            <ci_upper_limit>2.4079</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2391220 (M2) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.6404</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0744</ci_lower_limit>
            <ci_upper_limit>2.5048</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2487818 (M4) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.4931</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0876</ci_lower_limit>
            <ci_upper_limit>2.0498</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506102 (M5) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.6222</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1594</ci_lower_limit>
            <ci_upper_limit>2.2696</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.3145</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9896</ci_lower_limit>
            <ci_upper_limit>1.7462</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2) , GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2) , GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.8773" spread="39.9"/>
                    <measurement group_id="O2" value="205.7559" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3799" spread="44.7"/>
                    <measurement group_id="O2" value="47.1647" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6211" spread="40.1"/>
                    <measurement group_id="O2" value="31.7637" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4020" spread="36.6"/>
                    <measurement group_id="O2" value="11.3374" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7692" spread="41.0"/>
                    <measurement group_id="O2" value="50.1154" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4666" spread="31.2"/>
                    <measurement group_id="O2" value="21.0066" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7001" spread="66.5"/>
                    <measurement group_id="O2" value="31.9797" spread="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.4574</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0350</ci_lower_limit>
            <ci_upper_limit>2.0523</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.9375</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3919</ci_lower_limit>
            <ci_upper_limit>2.6968</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.8312</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3342</ci_lower_limit>
            <ci_upper_limit>2.5133</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>2.0030</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4654</ci_lower_limit>
            <ci_upper_limit>2.7378</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.7113</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2818</ci_lower_limit>
            <ci_upper_limit>2.2847</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.9740</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5365</ci_lower_limit>
            <ci_upper_limit>2.5360</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.4603</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9081</ci_lower_limit>
            <ci_upper_limit>2.3484</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Percentage of AUCex</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0463" spread="0.03971"/>
                    <measurement group_id="O2" value="0.0486" spread="0.03445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1919" spread="0.14164"/>
                    <measurement group_id="O2" value="0.4176" spread="0.38893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5756" spread="0.89564"/>
                    <measurement group_id="O2" value="0.6763" spread="0.61031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6147" spread="0.17403"/>
                    <measurement group_id="O2" value="2.1559" spread="2.01781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2598" spread="0.10004"/>
                    <measurement group_id="O2" value="0.3689" spread="0.26189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2983" spread="0.27141"/>
                    <measurement group_id="O2" value="0.2787" spread="0.15617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Percentage AUCex of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage AUCex of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Percentage of AUCex</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1148" spread="0.26035"/>
                    <measurement group_id="O2" value="0.0601" spread="0.06032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2943" spread="0.32698"/>
                    <measurement group_id="O2" value="0.8105" spread="1.60084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2584" spread="0.30727"/>
                    <measurement group_id="O2" value="0.9054" spread="0.89147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5138" spread="0.22859"/>
                    <measurement group_id="O2" value="1.5924" spread="1.69300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2565" spread="0.28382"/>
                    <measurement group_id="O2" value="0.6875" spread="1.33005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2915" spread="0.25350"/>
                    <measurement group_id="O2" value="0.9412" spread="0.94415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2327" spread="0.23338"/>
                    <measurement group_id="O2" value="0.5256" spread="0.46352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.1035" spread="111.2"/>
                    <measurement group_id="O2" value="148.2504" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4861" spread="57.0"/>
                    <measurement group_id="O2" value="46.9368" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2803" spread="67.7"/>
                    <measurement group_id="O2" value="28.7930" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7177" spread="43.9"/>
                    <measurement group_id="O2" value="11.0208" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8516" spread="49.3"/>
                    <measurement group_id="O2" value="20.8451" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9052" spread="34.1"/>
                    <measurement group_id="O2" value="39.4939" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.9973</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1061</ci_lower_limit>
            <ci_upper_limit>3.6066</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.6509</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1285</ci_lower_limit>
            <ci_upper_limit>2.4150</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2391220 (M2) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.6421</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0732</ci_lower_limit>
            <ci_upper_limit>2.5125</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2487818 (M4) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.5169</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0994</ci_lower_limit>
            <ci_upper_limit>2.0930</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506102 (M5) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.6240</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1599</ci_lower_limit>
            <ci_upper_limit>2.2736</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.3143</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9887</ci_lower_limit>
            <ci_upper_limit>1.7470</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: AUC (0-t) of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: AUC (0-t) of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.5322" spread="39.9"/>
                    <measurement group_id="O2" value="205.6322" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1105" spread="44.9"/>
                    <measurement group_id="O2" value="46.7771" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4564" spread="40.3"/>
                    <measurement group_id="O2" value="31.4750" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3023" spread="36.8"/>
                    <measurement group_id="O2" value="11.1555" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5334" spread="41.2"/>
                    <measurement group_id="O2" value="49.7669" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3456" spread="31.4"/>
                    <measurement group_id="O2" value="20.8080" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5914" spread="66.8"/>
                    <measurement group_id="O2" value="31.8113" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.4566</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0344</ci_lower_limit>
            <ci_upper_limit>2.0513</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.9478</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3935</ci_lower_limit>
            <ci_upper_limit>2.7224</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.8392</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3350</ci_lower_limit>
            <ci_upper_limit>2.5340</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>2.0161</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4711</ci_lower_limit>
            <ci_upper_limit>2.7630</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.7303</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2932</ci_lower_limit>
            <ci_upper_limit>2.3151</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.9870</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5426</ci_lower_limit>
            <ci_upper_limit>2.5594</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.4646</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9086</ci_lower_limit>
            <ci_upper_limit>2.3609</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.705" spread="108.8"/>
                    <measurement group_id="O2" value="70.607" spread="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.046" spread="46.2"/>
                    <measurement group_id="O2" value="10.199" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.022" spread="55.0"/>
                    <measurement group_id="O2" value="8.025" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.650" spread="34.6"/>
                    <measurement group_id="O2" value="2.245" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.946" spread="41.7"/>
                    <measurement group_id="O2" value="4.672" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.411" spread="35.0"/>
                    <measurement group_id="O2" value="7.120" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.9786</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0557</ci_lower_limit>
            <ci_upper_limit>3.7084</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.2791</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9241</ci_lower_limit>
            <ci_upper_limit>1.7705</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2391220 (M2) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.2487</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8675</ci_lower_limit>
            <ci_upper_limit>1.7974</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2487818 (M4) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.1802</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9165</ci_lower_limit>
            <ci_upper_limit>1.5197</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506102 (M5) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.2726</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9520</ci_lower_limit>
            <ci_upper_limit>1.7012</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.0409</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7927</ci_lower_limit>
            <ci_upper_limit>1.3668</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Cmax of GSK1278863 and Its Metabolites.</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Cmax of GSK1278863 and Its Metabolites.</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.232" spread="42.6"/>
                    <measurement group_id="O2" value="112.142" spread="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.792" spread="40.8"/>
                    <measurement group_id="O2" value="8.846" spread="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.614" spread="34.7"/>
                    <measurement group_id="O2" value="7.723" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.241" spread="35.7"/>
                    <measurement group_id="O2" value="1.975" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.475" spread="38.8"/>
                    <measurement group_id="O2" value="8.926" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.333" spread="28.2"/>
                    <measurement group_id="O2" value="4.010" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.791" spread="65.5"/>
                    <measurement group_id="O2" value="5.081" spread="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.0097</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7122</ci_lower_limit>
            <ci_upper_limit>1.4316</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.7852</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2498</ci_lower_limit>
            <ci_upper_limit>2.5498</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.7337</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2343</ci_lower_limit>
            <ci_upper_limit>2.4353</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.7628</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2898</ci_lower_limit>
            <ci_upper_limit>2.4092</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.6413</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2055</ci_lower_limit>
            <ci_upper_limit>2.2347</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.8289</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3992</ci_lower_limit>
            <ci_upper_limit>2.3904</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.3367</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8288</ci_lower_limit>
            <ci_upper_limit>2.1557</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9867" spread="33.2"/>
                    <measurement group_id="O2" value="4.4054" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1830" spread="26.9"/>
                    <measurement group_id="O2" value="5.6415" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6559" spread="38.3"/>
                    <measurement group_id="O2" value="3.6385" spread="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1966" spread="23.4"/>
                    <measurement group_id="O2" value="2.7314" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1287" spread="26.0"/>
                    <measurement group_id="O2" value="3.2641" spread="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9432" spread="22.8"/>
                    <measurement group_id="O2" value="3.9414" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>0.9050</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6900</ci_lower_limit>
            <ci_upper_limit>1.1869</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>0.7415</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5617</ci_lower_limit>
            <ci_upper_limit>0.9787</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2391220 (M2) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>0.7299</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4387</ci_lower_limit>
            <ci_upper_limit>1.2145</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2487818 (M4) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.1703</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9000</ci_lower_limit>
            <ci_upper_limit>1.5219</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506102 (M5) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>0.9585</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6664</ci_lower_limit>
            <ci_upper_limit>1.3786</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.0004</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7833</ci_lower_limit>
            <ci_upper_limit>1.2778</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: T1/2 of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: T1/2 of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5251" spread="27.4"/>
                    <measurement group_id="O2" value="4.2792" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8118" spread="21.2"/>
                    <measurement group_id="O2" value="4.7439" spread="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1059" spread="47.8"/>
                    <measurement group_id="O2" value="3.0578" spread="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4087" spread="30.8"/>
                    <measurement group_id="O2" value="3.3108" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6675" spread="20.2"/>
                    <measurement group_id="O2" value="4.4967" spread="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8096" spread="38.4"/>
                    <measurement group_id="O2" value="2.9947" spread="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2869" spread="21.2"/>
                    <measurement group_id="O2" value="3.5510" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.0574</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7876</ci_lower_limit>
            <ci_upper_limit>1.4197</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.0143</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7332</ci_lower_limit>
            <ci_upper_limit>1.4032</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.0380</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7695</ci_lower_limit>
            <ci_upper_limit>1.4002</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.3427</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7635</ci_lower_limit>
            <ci_upper_limit>2.3615</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.0296</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6996</ci_lower_limit>
            <ci_upper_limit>1.5151</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.2721</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8409</ci_lower_limit>
            <ci_upper_limit>1.9245</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Mean</param_type>
            <param_value>1.2072</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9398</ci_lower_limit>
            <ci_upper_limit>1.5508</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS Mean for GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.50" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Data was not calculable for the metabolite GSK2506104 (M3) due to matrix-related suppression during the bio-analysis of the Part 1 pharmacokinetic plasma samples.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.50" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6822</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
            <estimate_desc>Median Difference in GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5767</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2391220 (M2)(Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5880</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2487818 (M4)(Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7716</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2506102 (M5)(Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4093</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9837</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Tmax of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Tmax of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6224</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
            <estimate_desc>Median Difference in GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8042</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8423</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5207</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8423</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8042</p_value>
            <p_value_desc>P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Median Difference in GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>3 hours, 12 hours and 24 hours post-dose</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863; 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27989" spread="0.261668"/>
                    <measurement group_id="O2" value="0.11076" spread="0.070114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK1278863; 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK1278863; 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47750" spread="1.779468"/>
                    <measurement group_id="O2" value="2.85875" spread="1.129961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76525" spread="0.656087"/>
                    <measurement group_id="O2" value="0.22463" spread="0.119826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06460" spread="0.089209"/>
                    <measurement group_id="O2" value="0.00963" spread="0.017963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24463" spread="1.506964"/>
                    <measurement group_id="O2" value="1.86813" spread="0.760479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29301" spread="0.338773"/>
                    <measurement group_id="O2" value="0.04769" spread="0.031411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01201" spread="0.023617"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64588" spread="0.242321"/>
                    <measurement group_id="O2" value="0.43175" spread="0.165059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13024" spread="0.109089"/>
                    <measurement group_id="O2" value="0.04143" spread="0.031140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00923" spread="0.026092"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86250" spread="1.402241"/>
                    <measurement group_id="O2" value="2.57000" spread="1.010262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71075" spread="0.601452"/>
                    <measurement group_id="O2" value="0.23938" spread="0.121781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06315" spread="0.104994"/>
                    <measurement group_id="O2" value="0.00829" spread="0.015374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42725" spread="0.552287"/>
                    <measurement group_id="O2" value="0.89338" spread="0.334179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22973" spread="0.199514"/>
                    <measurement group_id="O2" value="0.06548" spread="0.035504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01470" spread="0.028580"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25375" spread="0.646771"/>
                    <measurement group_id="O2" value="2.03738" spread="0.807331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63125" spread="0.379804"/>
                    <measurement group_id="O2" value="0.32075" spread="0.163981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07580" spread="0.110738"/>
                    <measurement group_id="O2" value="0.01053" spread="0.020023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>3 hours, 12 hours and 24 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
          <units>Nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863; 3 hours; n=6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24213" spread="2.475347"/>
                    <measurement group_id="O2" value="0.15692" spread="0.138726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK1278863; 12 hours; n=7, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04343" spread="0.114901"/>
                    <measurement group_id="O2" value="0.01527" spread="0.037396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK1278863; 24 hours; n=7, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 3 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32625" spread="2.139472"/>
                    <measurement group_id="O2" value="2.13700" spread="1.276959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 12 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81263" spread="0.600031"/>
                    <measurement group_id="O2" value="0.24371" spread="0.079803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 24 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30654" spread="0.729605"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 3 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91375" spread="1.441219"/>
                    <measurement group_id="O2" value="1.57633" spread="0.937244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 12 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40141" spread="0.560638"/>
                    <measurement group_id="O2" value="0.07793" spread="0.033300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 24 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00839" spread="0.015586"/>
                    <measurement group_id="O2" value="0.00454" spread="0.012019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 3 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78213" spread="0.314177"/>
                    <measurement group_id="O2" value="0.31091" spread="0.213793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 12 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25856" spread="0.425759"/>
                    <measurement group_id="O2" value="0.04796" spread="0.035510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 24 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 3 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68625" spread="1.839883"/>
                    <measurement group_id="O2" value="1.94271" spread="1.262970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 12 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75350" spread="0.496638"/>
                    <measurement group_id="O2" value="0.27014" spread="0.122830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 24 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04093" spread="0.029445"/>
                    <measurement group_id="O2" value="0.00819" spread="0.021657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 3 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86763" spread="0.713958"/>
                    <measurement group_id="O2" value="0.73530" spread="0.451869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 12 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34200" spread="0.412505"/>
                    <measurement group_id="O2" value="0.07879" spread="0.023474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 24 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 3 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47825" spread="0.965944"/>
                    <measurement group_id="O2" value="1.26771" spread="0.871839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 12 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75363" spread="0.597207"/>
                    <measurement group_id="O2" value="0.29429" spread="0.153615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 24 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29830" spread="0.720919"/>
                    <measurement group_id="O2" value="0.00454" spread="0.012019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818, GSK2506102, GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.</description>
        <time_frame>3 hours, 12 hours and 24 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818, GSK2506102, GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
          <units>Percentage of unbound drug in plasma</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863; 3 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0034" spread="0.00109"/>
                    <measurement group_id="O2" value="0.0028" spread="0.00019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK1278863; 12 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK1278863; 24 hours; n=8,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 3 hours; n=8,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3379" spread="0.03573"/>
                    <measurement group_id="O2" value="0.3495" spread="0.05135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 12 hours; n=8,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3540" spread="0.02186"/>
                    <measurement group_id="O2" value="0.3355" spread="0.02172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 24 hours; n=4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3861" spread="0.02827"/>
                    <measurement group_id="O2" value="0.3902" spread="0.07149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 3 hours; n=8,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3080" spread="0.03085"/>
                    <measurement group_id="O2" value="0.2925" spread="0.01981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 12 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3071" spread="0.03419"/>
                    <measurement group_id="O2" value="0.2402" spread="0.02431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 24 hours; n=2,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3508" spread="0.00191"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 3 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2565" spread="0.04573"/>
                    <measurement group_id="O2" value="0.2441" spread="0.03397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 12 hours; n=8, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2517" spread="0.04022"/>
                    <measurement group_id="O2" value="0.2335" spread="0.02679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 24 hours; n=1, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2723" spread="NA">Data was not available as standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 3 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 12 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 24 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 3 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2469" spread="0.04315"/>
                    <measurement group_id="O2" value="0.2461" spread="0.03264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 12 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2550" spread="0.03166"/>
                    <measurement group_id="O2" value="0.2295" spread="0.01509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 24 hours; n=2, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3005" spread="0.03734"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 3 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3519" spread="0.04431"/>
                    <measurement group_id="O2" value="0.3844" spread="0.06838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 12 hours; n=8, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3771" spread="0.02114"/>
                    <measurement group_id="O2" value="0.3565" spread="0.02558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 24 hours; n=6, 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3817" spread="0.04449"/>
                    <measurement group_id="O2" value="0.3716" spread="0.02411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites (GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13)). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.</description>
        <time_frame>3 hours, 12 hours and 24 hours post-dose</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites (GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13)). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed (represented by n=X in category titles).</population>
          <units>Percentage of unbound drug in plasma</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK1278863; 3 hours; n=6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0134" spread="0.02369"/>
                    <measurement group_id="O2" value="0.0032" spread="0.00090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK1278863; 12 hours; n=1, 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1231" spread="NA">Data was not available as standard deviation could not be calculated for single participant..</measurement>
                    <measurement group_id="O2" value="0.1246" spread="NA">Data was not available as standard deviation could not be calculated for single participant..</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK1278863; 24 hours; n=8,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 3 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3191" spread="0.02263"/>
                    <measurement group_id="O2" value="0.3343" spread="0.06101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 12 hours; n=7, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3305" spread="0.03497"/>
                    <measurement group_id="O2" value="0.3174" spread="0.02174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220 (M2); 24 hours; n=5, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4099" spread="0.04797"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 3 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2762" spread="0.02792"/>
                    <measurement group_id="O2" value="0.2857" spread="0.03897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 12 hours; n=7, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2850" spread="0.03110"/>
                    <measurement group_id="O2" value="0.2766" spread="0.03608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818 (M4); 24 hours; n=2, 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3116" spread="0.07106"/>
                    <measurement group_id="O2" value="0.3387" spread="NA">Data was not available as standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 3 hours; n=8, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2339" spread="0.02704"/>
                    <measurement group_id="O2" value="0.2171" spread="0.06728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 12 hours; n=7, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2483" spread="0.03166"/>
                    <measurement group_id="O2" value="0.2191" spread="0.02903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102 (M5); 24 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 3 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2904" spread="0.02480"/>
                    <measurement group_id="O2" value="0.2938" spread="0.02618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 12 hours; n=7, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2970" spread="0.02959"/>
                    <measurement group_id="O2" value="0.2845" spread="0.02193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104 (M3); 24 hours; n=6, 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3267" spread="0.03171"/>
                    <measurement group_id="O2" value="0.3016" spread="NA">Data was not available as standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 3 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2491" spread="0.02989"/>
                    <measurement group_id="O2" value="0.2444" spread="0.04833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 12 hours; n=7, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2500" spread="0.03259"/>
                    <measurement group_id="O2" value="0.2346" spread="0.02031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398 (M6); 24 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and Standard Deviation were not calculable because concentration values were below detectable levels, but were imputed in the analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 3 hours; n=8, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3595" spread="0.02324"/>
                    <measurement group_id="O2" value="0.3569" spread="0.03504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 12 hours; n=7, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3527" spread="0.03957"/>
                    <measurement group_id="O2" value="0.3386" spread="0.01580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401 (M13); 24 hours; n=5, 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4154" spread="0.03151"/>
                    <measurement group_id="O2" value="0.3845" spread="NA">Data was not available as standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863</title>
        <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points. Pharmacodynamic Population comprised of all participants in the Safety Population who had at least one pharmacodynamic assessment.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
        <population>Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863</title>
          <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points. Pharmacodynamic Population comprised of all participants in the Safety Population who had at least one pharmacodynamic assessment.</description>
          <population>Pharmacodynamic Population</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.898" spread="36.8476"/>
                    <measurement group_id="O2" value="28.391" spread="13.1904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Cmax, EPO Following Administration of GSK1278863</title>
        <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
        <population>Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Cmax, EPO Following Administration of GSK1278863</title>
          <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
          <population>Pharmacodynamic Population</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.933" spread="20.2602"/>
                    <measurement group_id="O2" value="45.871" spread="35.1537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863</title>
        <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
        <population>Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863</title>
          <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
          <population>Pharmacodynamic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="10.0" lower_limit="8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Tmax, EPO Following Administration of GSK1278863</title>
        <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
        <population>Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Tmax, EPO Following Administration of GSK1278863</title>
          <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
          <population>Pharmacodynamic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="0" upper_limit="48"/>
                    <measurement group_id="O2" value="10.0" lower_limit="6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863</title>
        <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
        <population>Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863</title>
          <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
          <population>Pharmacodynamic Population</population>
          <units>Hours* International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1262.3724" spread="1148.34702"/>
                    <measurement group_id="O2" value="697.7140" spread="393.05978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: AUC (0-t, EPO) Following Administration of GSK1278863</title>
        <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
        <time_frame>Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose</time_frame>
        <population>Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: AUC (0-t, EPO) Following Administration of GSK1278863</title>
          <description>Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.</description>
          <population>Pharmacodynamic Population</population>
          <units>Hours* International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1258.6211" spread="683.32848"/>
                    <measurement group_id="O2" value="1061.7549" spread="647.67154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. Safety Population comprised of all participants who received at least one dose of study medication.</description>
        <time_frame>Up to 16 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. Safety Population comprised of all participants who received at least one dose of study medication.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With AEs and SAEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment.</description>
        <time_frame>Up to 16 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With AEs and SAEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline</title>
        <description>Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter (g/L) for hemoglobin, &lt;3 or &gt;20 x10^9 cells per liter (cells/L) for leukocytes, &lt;0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 x10^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given [e.g.], High to High), or whose value became within range, were recorded in &quot;To within Range or No Change&quot; category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
        <time_frame>Baseline (Screening) and up to Day 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline</title>
          <description>Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter (g/L) for hemoglobin, &lt;3 or &gt;20 x10^9 cells per liter (cells/L) for leukocytes, &lt;0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 x10^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given [e.g.], High to High), or whose value became within range, were recorded in &quot;To within Range or No Change&quot; category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
        <description>Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, &lt;3 or &gt;20 x10^9 cells/L for leukocytes, &lt;0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 x10^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in &quot;To within Range or No Change&quot; category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
        <time_frame>Baseline (Screening) and up to Day 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
          <description>Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt;0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, &lt;3 or &gt;20 x10^9 cells/L for leukocytes, &lt;0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 x10^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in &quot;To within Range or No Change&quot; category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
        <description>Blood samples were collected for analysis of following parameters. PCI ranges were &lt;30g/L (albumin), &lt;2 or &gt;2.75 millimoles/L(mmol/L) (calcium), &lt;3 or &gt;9mmol/L(glucose), &gt;=2 times Upper limit of Normal(ULN) units/L(U/L) (alanine aminotransferase [ALT]), &gt;=2 times ULN U/L (alkaline phosphatase), &gt;=2 times ULN U/L(aspartate aminotransferase [AST]), &gt;=1.5 times ULN micromoles/L (µmol/L)(bilirubin), &lt;3 or &gt;5.5mmol/L(potassium), and &lt;130 or &gt;150mmol/L(sodium). Participants were counted in worst case category that their value changes to (low,within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
        <time_frame>Baseline (Screening) and up to Day 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
          <description>Blood samples were collected for analysis of following parameters. PCI ranges were &lt;30g/L (albumin), &lt;2 or &gt;2.75 millimoles/L(mmol/L) (calcium), &lt;3 or &gt;9mmol/L(glucose), &gt;=2 times Upper limit of Normal(ULN) units/L(U/L) (alanine aminotransferase [ALT]), &gt;=2 times ULN U/L (alkaline phosphatase), &gt;=2 times ULN U/L(aspartate aminotransferase [AST]), &gt;=1.5 times ULN micromoles/L (µmol/L)(bilirubin), &lt;3 or &gt;5.5mmol/L(potassium), and &lt;130 or &gt;150mmol/L(sodium). Participants were counted in worst case category that their value changes to (low,within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT ; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT;To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST;To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
        <description>Blood samples were collected for analysis of following parameters. PCI ranges were &lt;30g/L (albumin), &lt;2 or &gt;2.75 mmol/L (calcium), &lt;3 or &gt;9mmol/L (glucose), &gt;=2 times ULN U/L (ALT), &gt;=2 times ULN U/L (alkaline phosphatase), &gt;=2 times ULN U/L (AST), &gt;=1.5 times ULN µmol/L (bilirubin), &lt;3 or &gt;5.5 mmol/L (potassium), and &lt;130 or &gt;150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
        <time_frame>Baseline (Screening) and up to Day 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline</title>
          <description>Blood samples were collected for analysis of following parameters. PCI ranges were &lt;30g/L (albumin), &lt;2 or &gt;2.75 mmol/L (calcium), &lt;3 or &gt;9mmol/L (glucose), &gt;=2 times ULN U/L (ALT), &gt;=2 times ULN U/L (alkaline phosphatase), &gt;=2 times ULN U/L (AST), &gt;=1.5 times ULN µmol/L (bilirubin), &lt;3 or &gt;5.5 mmol/L (potassium), and &lt;130 or &gt;150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT ; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT;To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT ; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST;To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Abnormal Urinalysis Findings</title>
        <description>Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.</description>
        <time_frame>Up to Day 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Moderate Hepatic Impairment Participants</title>
            <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Healthy Participants</title>
            <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Abnormal Urinalysis Findings</title>
          <description>Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants With Abnormal Urinalysis Findings</title>
        <description>Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.</description>
        <time_frame>Up to Day 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Mild Hepatic Impairment Participants</title>
            <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Healthy Participants</title>
            <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Abnormal Urinalysis Findings</title>
          <description>Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study treatment up to 16 days in each part of the study.</time_frame>
      <desc>SAEs and Non-SAEs were reported for Safety Population comprised of all participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Moderate Hepatic Impairment Participants</title>
          <description>Participants with moderate hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during Part 1 of the study. This group included at least one participant with a Child-Pugh score of 7, 8 and 9 for moderate hepatic impairment.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Healthy Participants</title>
          <description>Healthy control participants, matched to moderate hepatic impairment participants in gender, age and Body mass index (BMI) received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state.</description>
        </group>
        <group group_id="E3">
          <title>Part 2: Mild Hepatic Impairment Participants</title>
          <description>Participants with mild hepatic impairment received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state during part 2 of the study. This group included at least one participant with a Child-Pugh score of 5 and 6 for mild hepatic impairment.</description>
        </group>
        <group group_id="E4">
          <title>Part 2: Healthy Participants</title>
          <description>Healthy control participants, matched to mild hepatic impairment participants in gender, age and BMI received 6 mg of GSK1278863 as a single oral dose tablet in the fasted state in part 2 of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

